Skip to content

Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait in Patients With Cerebellar Ataxia Gene

Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait in Patients With Cerebellar Ataxia Gene

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02903290
Enrollment
15
Registered
2016-09-16
Start date
2017-01-25
Completion date
2023-01-31
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebellar Ataxia

Brief summary

Genetic cerebellar ataxias involves progressive degeneration of the cerebellum. Their overall prevalence is estimated at 2-4 cases per 100 000 people. These diseases are manifested by a static and kinetic cerebellar syndrome characterized by impaired balance, coordination, and an ataxic gait. To date, no therapy is available for patients and physical therapy is essential and recommended. The evolution of the pathology causes a degradation of walking, increased instability and risk of falling. In one year, between 74% and 93% of patients reported having fallen at least once. Falls prevention by understanding the mechanisms affecting stability is a major issue in the management of these patients physiotherapy. The analysis of the literature, we assume that there exists a trio fatigue - instability - energy expenditure in which the three parameters would influence each other. To date, we do not have data to characterize these interrelationships and their evolution over time. STUDY OBJECTIVES: The main objective is to study the relationship between changes in energy expenditure and changes in instability when walking at one year in patients with cerebellar ataxia gene. The secondary objectives are to study, after one year of development, the relationship between fatigue, instability, energy consumption, the number of falls, the severity of ataxia and quality of life. CONDUCT OF THE STUDY: This is a pilot, multicenter, interventional. The projected duration of patient recruitment will be 12 months and the total number of patients will be included in 15. The duration of participation in this study is 12 months for each patient. The anticipated duration of the study is 30 months. Development of the study: Patients included will perform two sets (S1 and S2) tests a year apart including the evaluation of ataxia according Scale for the assessment and rating of ataxia (SARA); measuring the quality of life through SF36 (The Short Form (36)) Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®.

Interventions

OTHERLongitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait

Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait

OTHERwalking track GAITRite,manual dynamometer, and treadmill

walking track GAITRite,manual dynamometer, and treadmill

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patient aged 18 to 60; * Patient with cerebellar syndrome genetically determined or evidence of inheritance; * Patient walking more than 50 meters independently, with or without technical assistance; * Patient likely to be followed regularly for at least one year; * Patient has given written informed consent; * Patient affiliated to Social Security.

Exclusion criteria

* Patient with any other injuries not attributable to the pathology and can influence the running tests according to physician judgment; * Patient with any disease or condition incompatible to the success of the study according to the doctor's judgment; * Patient not strolling or sauntering only with a third person to help; * Major person under guardianship; * People hospitalized without his consent and not protected by law; * Nobody deprived of liberty; * Patients speakers.

Design outcomes

Primary

MeasureTime frameDescription
Pre physical activity scores (Gilette Gait Index (GVI)) to pre exercise walkingAt one yearThe main objective is to investigate the relationship between changes in energy expenditure and changes in instability when walking at one year in patients with cerebellar ataxia gene.
Oxygen consumption to pre exercise walkingAt one yearThe main objective is to investigate the relationship between changes in energy expenditure and changes in instability when walking at one year in patients with cerebellar ataxia gene.
Pre physical activity scores (Functional Ambulation Performance Score (FAPS)) to pre exercise walkingAt one yearThe main objective is to investigate the relationship between changes in energy expenditure and changes in instability when walking at one year in patients with cerebellar ataxia gene.

Secondary

MeasureTime frameDescription
Functional Systems Scores (FSS) scoreAt one yearStudy, after one year of development, the relationship between fatigue, instability, energy consumption, the number of falls, the severity of ataxia and quality of life.
Visual Analog Scale (VAS) tirednessAt one yearStudy, after one year of development, the relationship between fatigue, instability, energy consumption, the number of falls, the severity of ataxia and quality of life.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026